This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Phenylpiracetam
Russian-developed phenyl-substituted piracetam analog created in 1983 for Soviet cosmonauts — the only racetam on the WADA prohibited list…
Aliases (15)
Overview
What is Phenylpiracetam?
Phenylpiracetam (Phenotropil, Carphedon) is a Russian-developed pyrrolidinone nootropic, a phenylated derivative of piracetam with markedly enhanced potency, lipophilicity, and stimulant-like cognitive effects. It is registered in Russia for cognitive disorders and is banned by WADA.
Key Benefits
Reported to enhance focus, motivation, physical performance, cold tolerance, and learning, with a stimulant-like subjective profile but without classic catecholamine release. Tolerance develops rapidly to subjective effects, limiting daily use.
Mechanism of Action
Modulates AMPA glutamate receptors, NMDA receptors, and nicotinic acetylcholine receptors. Increases dopamine, norepinephrine, and serotonin levels and enhances dopamine D1/D2 receptor density. Inhibits dopamine reuptake to a mild degree.
Pharmacokinetics
▸Brand options8 known
StatusUnscheduled in US (legal gray-market import for personal use). Rx-only in Russia (registered as Phenotropil 2003; off-market 2017-2018; reissued as Nanotropil Novo® and Aktitropil® by Pharmstandard ~2020+). WADA-banned in-competition since **1998** (S6 stimulant) — this is the date in WADA prohibited-list documentation; some sources misstate as 2002, which is when high-profile athlete cases began under the new code.
Peptide Interactions
/ citicoline (the user's V stack includes 500 mg citicoline daily): Mandatory pairing to prevent racetam headache and amplify cognitive effect. Pre-dose by 3…
Theoretical synergy via increased DA substrate when reuptake is blocked. Anecdotal reports mixed but mostly positive. Try 500-1000 mg with phenylpiracetam dose.
Different mechanism (HACU enhancement vs. DAT inhibition), no cross-tolerance reported. Can be used on alternate days — pramiracetam for sustained daily cogn…
Similar PRN profile, complementary mechanism (thiamine derivative, mild DA via different pathway). Can stack on the same PRN day for combined drive + cogniti…
Different DAT-binding kinetics; functionally synergistic for wakefulness + drive, but don't stack same-day on a routine basis — phenylpiracetam should be a *…
(the user's V stack has 200 mg): Smoothing partner — softens any mild irritability/agitation, no efficacy compromise.
(the user's V stack): Neutral-positive; helps sleep onset on phenylpiracetam days if dosed PM.
(users in this archetype often already take): Synergistic for the physical-performance arm; both improve high-output cognitive + physical work.
(the user's V stack): Synergistic for endurance / training-day applications.
(modafinil daily-stack, amphetamine, methylphenidate, bromantane): additive sympathetic + DA tone, hypertension/anxiety/sleep risk. Pick one per day.
(>200 mg): additive stimulation, jitter risk. Low caffeine (50-100 mg) is fine.
not a pharmacological interaction concern, but the GABA-B agonism + stim lift produces a "rollercoaster" subjective profile most users dislike. Skip.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety
- Common (>10% users):
- Insomnia / sleep onset delay if dosed past mid-afternoon — most common cause of bad outcomes; resolves with AM-only dosing.
- Mild headache in choline-undosed users — fully preventable with co-dosed alpha-GPC or CDP-choline.
- Mild irritability / agitation — typically dose-dependent, more common at 200+ mg, often resolves with food + L-theanine co-dose.
- Tolerance buildup — universal at >5 consecutive days of daily use, partial within 1-2 weeks. Functionally a side effect because it forces cycling.
- Less common (1-10%):
- Mild appetite suppression (DAT inhibitor profile, similar to modafinil but milder)
- Mild HR / BP elevation (modest sympathetic activation, smaller magnitude than modafinil)
- Mild GI discomfort if dosed on empty stomach in sensitive users
- Dry mouth
- Mild flushing / warmth (transient, especially first doses)
- Psychomotor agitation / "wired" feeling at higher doses (>200 mg)
- Rare-serious (<1% but worth knowing):
- Hypertension at supratherapeutic doses — documented in Russian clinical literature at >400 mg/day. Not a concern at 100-200 mg.
- No documented cases of dependence, addiction, or withdrawal in the human literature. Tolerance is functional, not addiction-pattern.
- Theoretical seizure threshold concerns — like piracetam, phenylpiracetam may lower seizure threshold in susceptible individuals. Not contraindicated in healthy users; caution if any seizure history.
- No documented hepatotoxicity (consistent with non-hepatic metabolism).
- No documented cardiac arrhythmia signal at therapeutic doses.
- Specific watch periods:
- Days 1-7 of any new pulse: monitor for excessive HR/BP if normally stim-sensitive; monitor sleep quality (afternoon dosing kills sleep).
- Beyond 14 days continuous: tolerance is the main effect, not a safety signal — but you'll be wasting product. Cycle off.
- Pediatric / under-18: Russian pediatric use exists but Western consensus is to avoid in developing brains. a 20-year-old in this archetype is past the highest-risk window but still in the "favor lowest brain-development risk options" range — phenylpiracetam's brain-dev profile is benign at PRN dosing.
- Interaction risks:
- Additive with other DAT inhibitors (modafinil, methylphenidate, amphetamine, cocaine, bromantane). Avoid same-day stacking — sympathetic + DA tone goes additive, with risk of overstimulation, hypertension, anxiety, sleep wreck.
- MAOIs (theoretical): DA reuptake inhibitor + MAO inhibition could theoretically produce hypertensive episode. Selegiline at 1-2.5 mg (MAO-B selective) is probably fine; non-selective MAOIs are not relevant to the user's plan.
- Caffeine: mild additive — usable at low caffeine doses (<100 mg) but stacking 200 mg phenylpiracetam + 200 mg caffeine + 200 mg L-theanine is overshoot for most users.
- L-tyrosine: theoretically synergistic (more substrate for DA synthesis when reuptake is blocked) — anecdotal reports mixed.
- Choline (alpha-GPC, CDP-choline): synergistic, prevents headache.
References
Wikipedia — Phenylpiracetam
comprehensive overview, mechanism, pharmacokinetics, regulatory status, key research history.
View StudyWikipedia — MRZ-9547
pure R-phenylpiracetam, Merz development for Parkinson's fatigue, program status.
View StudyZvejniece et al. (2017) — S-phenylpiracetam, a selective DAT inhibitor (PubMed 28743458)
molecular pharmacology, DAT IC50, body weight effects of S-enantiomer.
View StudySavchenko et al. (2005) — The phenotropil treatment of the consequences of brain organic lesions (PubMed 16447562)
99-patient encephalopathy trial (commonly cited as "the 400-pt RCT" but actually 99 patients open-label).
View StudyFirstova et al. (2011) — Effects of scopolamine and phenotropil on rat brain neurotransmitter receptors
receptor density data: D1 +16%, D2 +29%, D3 +62%, BZ +25%; NMDA + AChR density modulation.
View StudyBobkov et al. (1983) — Pharmacological characteristics of a new phenyl analog of piracetam (4-phenylpiracetam)
original Russian characterization, hypoxia/cold tolerance data.
View StudyAhmedov et al. (2008) — DAT inhibition and effort-based decision-making (Tanda et al. 2009)
375% work output increase in rats.
View StudyCarphedon at the Crossroads (Juniper Publishers, 2018)
review of WADA status, athlete cases, dual-use framing.
View StudyOlympics.com — IOC sanctions Pyleva (2006 Turin)
primary-source on the 2006 Turin Olympic case.
View StudyWADA 2026 Prohibited List
current S6 stimulant classification for fonturacetam (carphedon).
View StudyPsychonautWiki — Phenylpiracetam
subjective effects, harm reduction, dosing summaries.
View StudyNootropics Expert — Phenylpiracetam
biohacker-side dosing + choline pairing protocols.
View StudyRacetam.net — Phenylpiracetam Scientific Review
mechanism + clinical-trial summary.
View StudySelfDecode — Phenylpiracetam dosage and side effects
side effect prevalence summaries.
View StudyLift Mode — Phenylpiracetam Tolerance and Cycling (Medium)
tolerance kinetics anecdotal compilation.
View StudyRUPharma — Aktitropil® product page
current pharma-grade Russian sourcing, $/dose data.
View StudyRUPharma — Nanotropil Novo® product page
alternative pharma-grade brand, same Pharmstandard manufacturer.
View StudyRUPharma — Phenotropil® product page
original brand reissued post-2020 licensing fix.
View StudyCosmicNootropic — Phenotropil product page
alternative Russian-pharma sourcing.
View StudyGromova & Torshin (2024) — Pharmacological effects of fonturacetam (Actitropil) in Korsakov Journal
recent Russian review on phenylpiracetam clinical use prospects.
View StudyTanda et al. (2009) — DAT inhibitors and effort-based motivation
animal effort-output behavioral data underlying the "drive without jitter" phenomenology.
View StudyPatent EP2891491A1 — Use of (R)-phenylpiracetam for sleep disorders
Merz/Pharmstandard patent positioning, R-enantiomer preference.
View StudyLatest research
- reviewPharmacological effects of fonturacetam (Actitropil) — Korsakov Journal reviewRecent Russian review on phenylpiracetam clinical use prospects (Gromova & Torshin).
- reviewS-phenylpiracetam, a selective DAT inhibitor — molecular pharmacologyDAT IC50 characterization and S-enantiomer body weight effects (Zvejniece et al.).
- observationalPhenotropil treatment of consequences of brain organic lesions99-patient open-label encephalopathy trial — improved motor coordination, memory, attention, EEG normalization.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.